NCT03601897View on ClinicalTrials.gov

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

October 25, 2018

Primary Completion Date

May 23, 2022

Study Completion Date

May 23, 2022

Conditions
Locally Advanced or Metastatic Solid Tumor
Interventions
DRUG

Rebastinib

Administered orally

DRUG

Paclitaxel

Paclitaxel administered by IV infusion at 80 mg/m\^2

Trial Locations (14)

10467

Montefiore Medical Center, The Bronx

11042

Northwell Health/Monter Cancer Center, Lake Success

19111

Fox Chase Cancer Center, Philadelphia

35233

University of Alabama Comprehensive Cancer Center, Birmingham

37203

Sarah Cannon Research Institute, Nashville

43210

Ohio State University Wexner Medical Center, Columbus

60611

Northwestern University Feinberg School of Medicine, Chicago

66160

The University of Kansas Clinical Research Center, Kansas City

73104

University of Oklahoma Health Sciences Center, Oklahoma City

77030

MD Anderson Cancer Center, Houston

Oncology Consultants- Texas Medical Center, Houston

80045

University of Colorado Denver- Anschutz Medical Center, Aurora

02215

Dana-Farber, Boston

02905

Women & Infants Hospital, Providence

Sponsors
All Listed Sponsors
lead

Deciphera Pharmaceuticals, LLC

INDUSTRY

NCT03601897 - A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter